Invezz

Becton Dickinson and Company (BDX)

NYSE Market Closed

Becton, Dickinson and Co., widely known as BD, is a global medical technology company that supplies devices, systems and consumables used across hospitals, laboratories, pharmaceutical manufacturing and outpatient care. Its portfolio spans basic medical products as well as more specialised platforms, giving the company exposure to everyday healthcare demand and higher-growth areas such as medication management, drug delivery and minimally invasive procedures.

BD’s medical essentials operations include many of its long-established products, such as syringes, needles, catheters and infection prevention items. These products are used in routine clinical care and benefit from BD’s scale, manufacturing capabilities and distribution reach. The connected care business includes the Alaris infusion platform, Pyxis automated medication dispensing systems and pharmacy automation technologies that help healthcare providers manage drug delivery, inventory and patient safety.

The biopharma systems business supplies prefillable syringes, autoinjectors and related components to pharmaceutical and biotechnology companies. This makes BD an important partner in the delivery of injectable medicines, including biologics and other therapies that require reliable, patient-friendly administration formats. Its interventional segment includes products used in surgery, peripheral vascular care and urology, supporting procedures that often aim to reduce invasiveness and improve recovery.

BD generates a majority of its revenue in the United States but operates internationally across healthcare systems with different clinical and regulatory needs. The company’s competitive position rests on brand recognition, regulatory expertise, manufacturing quality and long-standing relationships with hospitals and life sciences customers. Its breadth makes it a diversified supplier within the medical technology sector rather than a company dependent on a single product category.

154.48 USD
154.06 USD
−3.69 (-2.33%)
Pre-market

Last updated

Market Cap
$42,565,485,163
P/E
37.4
P/FCF
13.54
P/S
1.99
Enterprise Value
$59,031,485,163
Sector
Health Care
Industry
Health Care Equipment
Address
ONE BECTON DR, FRANKLIN LAKES, NJ, 07417-1880
globenewswire.com

Bloodstream Infection Testing Market Size to Reach USD 1,404.68 Million by 2035 | SNS Insider

26 Jun 2026, 20:30 PM
globenewswire.com

Enteric Disease Testing Market Worth USD 5.86 Billion by 2035 | SNS Insider

23 Jun 2026, 20:35 PM
globenewswire.com

Wound Irrigation Systems Market to Skyrocket USD 430.05 Million by 2035 as Chronic Wound Cases and Surgical Volumes Rise Worldwide | SNS Insider

03 Jun 2026, 23:00 PM
investing.com

3 Dividend Kings That Earn Their Crown Every Quarter

02 Jun 2026, 03:19 AM
globenewswire.com

Microneedle Drug Delivery Systems Market to Hit USD 14.37 Billion by 2035 Driven by Self-Administered Therapies – SNS Insider

26 May 2026, 15:30 PM
globenewswire.com

Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight

15 May 2026, 05:00 AM
globenewswire.com

Global HPV Testing and Pap Test Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight

13 May 2026, 05:00 AM
globenewswire.com

Pregnancy Detection Kits Market Analysis Report 2026 - Competitive Landscape, Opportunities, and Forecasts, 2021-2025 & 2025-2031

08 May 2026, 20:47 PM
globenewswire.com

China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and Sanofi

18 Apr 2026, 04:00 AM
globenewswire.com

[Latest] Global Pharmaceutical Microbiology QC Testing Market Size/Share Worth USD 17.65 Billion by 2035 at a 13.27% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)

11 Mar 2026, 07:00 AM
globenewswire.com

Pulmonary Artery Catheter Market Size to Reach USD 1.97 Billion by 2035 Caused by the Surging Critical Care Procedures Globally

17 Feb 2026, 22:00 PM
investing.com

3 Best Dividend Kings for 2026

05 Feb 2026, 07:17 AM
globenewswire.com

OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - Privacy, Digital Access, and Rapid Results Accelerate Adoption

04 Feb 2026, 02:00 AM
globenewswire.com

Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS Insider

13 Jan 2026, 01:52 AM
investing.com

Top 2026 Market Prediction and 3 Cheap Dividends to Play It

06 Jan 2026, 23:28 PM
investing.com

These Surging Dividend Stocks Are the Next AI Winners and Wall Street Hates Them

16 Dec 2025, 23:31 PM
globenewswire.com

Europe Glass Prefilled Syringes and Glass Vials Packaging Equipment Market Trends 2035

02 Dec 2025, 05:00 AM
globenewswire.com

U.S. Arteriovenous Fistula Devices Market Trends Analysis Report 2025-2033: Lucrative Opportunities Stem from Rising ESRD Cases, Driving Demand for AVF Solutions

19 Nov 2025, 22:57 PM
globenewswire.com

Cell-based Assays Market Size to Reach USD 35.34 Billion by 2032, Driven by Demand for Drug Discovery and Advanced Biotechnology Research – SNS Insider

30 Oct 2025, 21:59 PM
globenewswire.com

Connected Drug Delivery Devices Market Grows at 23.44% CAGR, Expected to Reach USD 61.08 billion by 2034

04 Oct 2025, 04:00 AM
Market Cap
$42,565,485,163
Enterprise Value
$59,031,485,163
P/E
37.4
P/B
1.76
P/S
1.99
EV / EBITDA
10.1
EV / Sales
2.76
EPS
4.13
Dividend Yield
2.78%
P/FCF
13.54
P/CF
10.91
Free Cash Flow
$3,143,000,000
ROE
4.72%
ROA
2.24%
Debt / Equity
0.72
Current Ratio
0.92
Quick Ratio
0.52
Cash
0.1
Avg Volume
$2,514,994
Fundamentals Snapshot Price
154.48

Income Statement

Line Item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Revenue 4.71B 5.25B 5.89B 5.51B 4.48B
Cost of revenue 2.56B 2.84B 3.09B 2.88B 2.62B
Gross profit 2.15B 2.41B 2.8B 2.63B 1.86B
Operating income 93M 601M 981M 921M 384M
EBITDA 1.15B 1.33B 1.74B 1.64B 1B
Net income -311M 382M 493M 574M 308M
Income taxes 76M 11M 17M 129M 43M
Interest expense -149M -153M -155M -152M -150M
Other operating expenses 599M 111M 129M 96M 128M
Total operating expenses 2.06B 1.81B 1.82B 1.71B 1.48B
Basic EPS -1.11 1.34 1.72 2 1.07
Diluted EPS -1.11 1.34 1.72 2 1.07

Balance Sheet

Line Item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Total assets 50.83B 54.84B 55.33B 54.9B 54.47B
Total liabilities 26.7B 29.56B 29.93B 29.43B 29.23B
Total equity 24.13B 25.28B 25.39B 25.47B 25.24B
Cash & equivalents 813M 740M 567M 735M 667M
Current assets 7.81B 8.91B 9.05B 8.94B 8.59B
Current liabilities 8.51B 8.76B 8.01B 8.16B 7.69B
Accounts payable 5.93B 6.14B 6.11B 6.35B 6.09B
Receivables 2.21B 2.51B 2.4B 2.94B 3.03B
Inventories 3.36B 4.09B 3.15B 3.95B 3.72B
Goodwill 25.96B 26.62B 25.96B 26.6B 26.44B
Long-term debt 14.71B 16.92B 17.62B 17.53B 17.67B

Cash Flow

Line Item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Operating cash flow 673M 656M 1.35B 1.22B -205M
Investing cash flow -138M -183M -494M -336M -133M
Financing cash flow -472M -301M -809M -841M 269M
Change in cash 64M 174M 53M 51M -68M
Net income -108M 382M 493M 574M 1M
Kind Filing Date Link
edgar index 4 — BECTON DICKINSON & CO View Filing
form 4 Form 4 — Muhsin Bilal View Filing
form 4 Form 4 — Muhsin Bilal View Filing
edgar index 11-K — BECTON DICKINSON & CO View Filing
edgar index 11-K — BECTON DICKINSON & CO View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
edgar index 144 — BECTON DICKINSON & CO View Filing
form 4 Form 4 — Feld Michael View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
edgar index 144 — BECTON DICKINSON & CO View Filing
form 4 Form 4 — Garrison Michael David View Filing
edgar index 3 — BECTON DICKINSON & CO View Filing
form 3 Form 3 — Sinha Manish View Filing
form 3 Form 3 — Sinha Manish View Filing
form 3 Form 3 — Sinha Manish View Filing
form 3 Form 3 — Sinha Manish View Filing
form 3 Form 3 — Sinha Manish View Filing
form 3 Form 3 — Sinha Manish View Filing
form 3 Form 3 — Sinha Manish View Filing
form 3 Form 3 — Sinha Manish View Filing
form 3 Form 3 — Sinha Manish View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
edgar index 144 — BECTON DICKINSON & CO View Filing
form 4 Form 4 — Garrison Michael David View Filing
edgar index 25-NSE — BECTON DICKINSON & CO View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
edgar index 3 — BECTON DICKINSON & CO View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
form 3 Form 3 — Menziuso Peter View Filing
edgar index 144 — BECTON DICKINSON & CO View Filing
form 4 Form 4 — Menziuso Peter View Filing
form 4 Form 4 — Polen Thomas E Jr View Filing
form 4 Form 4 — Polen Thomas E Jr View Filing
form 4 Form 4 — Polen Thomas E Jr View Filing
form 4 Form 4 — Polen Thomas E Jr View Filing
edgar index 8-K — BECTON DICKINSON & CO View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
edgar index 144 — BECTON DICKINSON & CO View Filing
form 4 Form 4 — Feld Michael View Filing
edgar index SD — BECTON DICKINSON & CO View Filing
edgar index CERT — BECTON DICKINSON & CO View Filing
edgar index 8-K — BECTON DICKINSON & CO View Filing
edgar index 8-A12B — BECTON DICKINSON & CO View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G/A — BECTON DICKINSON & CO View Filing
edgar index 424B2 — BECTON DICKINSON & CO View Filing
edgar index 8-K — BECTON DICKINSON & CO View Filing
eight k text 8-K — 8-K View Filing
edgar index 424B2 — BECTON DICKINSON & CO View Filing
edgar index FWP — BECTON DICKINSON & CO View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
form 4 Form 4 — Byington Carrie L View Filing
form 4 Form 4 — Huffines Robert Luther View Filing
edgar index 10-Q — BECTON DICKINSON & CO View Filing
edgar index S-8 — BECTON DICKINSON & CO View Filing
edgar index S-8 — BECTON DICKINSON & CO View Filing
edgar index 8-K — BECTON DICKINSON & CO View Filing
edgar index 8-K/A — BECTON DICKINSON & CO View Filing
eight k text 8-K — 8-K View Filing
form 4 Form 4 — Roque Vitor View Filing
edgar index 8-K — BECTON DICKINSON & CO View Filing
edgar index SCHEDULE 13G — BECTON DICKINSON & CO View Filing
edgar index SCHEDULE 13G — BECTON DICKINSON & CO View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
edgar index 144 — BECTON DICKINSON & CO View Filing
form 4 Form 4 — Feld Michael View Filing
edgar index 8-K — BECTON DICKINSON & CO View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — BECTON DICKINSON & CO View Filing
form 4 Form 4 — Neal Shana Carol View Filing
edgar index 8-K — BECTON DICKINSON & CO View Filing
  • Trusted by 1M+ investors
  • Global coverage
  • Real-time market data
  • Independent & unbiased

Join thousands making smarter investment decisions.

Get started for free